Peter Edward Fecci
Assistant Professor of Neurosurgery
As the Director of both the Brain Tumor Immunotherapy Program and the Center for Brain and Spine Metastasis at Duke University, I focus our programmatic interests on the design, optimization, and monitoring of immune-based treatment platforms for patients with intracranial tumors, whether primary or metastatic. Within this broad scope, however, my own group looks more specifically at limitations to immunotherapeutic success, with a particular focus on understanding and reversing T cell dysfunction in patients with glioblastoma (GBM) and brain metastases. We employ a systematic approach to categorizing T cell dysfunction (Woroniecka et al, Clin Cancer Res 2018 Aug 15;24(16):3792-3802), and whereas our earlier work addressed concerns for regulatory T cell-induced tolerance, we now heavily study T cell ignorance and exhaustion, as well. Regarding the former, we recently published the novel phenomenon of S1P1-mediated bone marrow T cell sequestration in patients with intracranial tumors (Chongsathidkiet et al, Nat Medicine 2018 Sep;24(9):1459-1468). Regarding the latter, we have likewise recently identified and characterized exhaustion as a significant limitation to T-cell function within GBM (Woroniecka et al, Clin Cancer Res 2018 Sep 1;24(17):4175-4186). I very much look to collaboratively integrate our approaches with others investigating innovative treatment options. I continue my focus on combining strategies for reversing T cell deficits with current and novel immune-based platforms as a means of deriving and improving rational and precise anti-tumor therapies. It is my sincerest desire to forge a career focused on co-operative, multi-disciplinary, organized brain tumor therapy. Ultimately, my goal is to help coordinate the efforts of a streamlined and effective center for brain tumor research and clinical care. I hope to play some role in ushering in a period where the science and treatment arms of brain tumor therapy suffer no disjoint, but instead represent the convergent efforts of researchers, neuro-oncologists, medical oncologists, radiation oncologists, biomedical engineers, and neurosurgeons alike. I hope to see such synergy become standard of care.
Appointments and Affiliations
- Assistant Professor of Neurosurgery
- Assistant Professor in Pathology
- Assistant Research Professor in Immunology
- Member of the Duke Cancer Institute
- Office Location: 201 Sands Bldg., Box 3050, Durham, NC 27710
- Office Phone: (919) 681-2610
- Email Address: email@example.com
- Massachusetts General Hospital, 2014
- Dana Farber Cancer Institute, 2012
- Massachusetts General Hospital, 2013
- Massachusetts General Hospital, 2008
- Ph.D. Duke University, 2007
- M.D. Duke University School of Medicine, 2007
Brain Tumor Immunotherapy
Cancer-Induced Immune Dysfunction
Awards, Honors, and Distinctions
- Paper of the Year. American Association of Physicists in Medicine. 2017
- Visting Scholar. National Institutes of Health. 2017
- Duke Health Scholars Award. Duke University School of Medicine. 2016
- Prince Mahidol Youth Mentor Award. Prince Mahidol Award Foundation. 2016
- Alpha Omega Alpha. Alpha Omega Alpha Medical Honor Society. 2015
- Resident Advocate Award. Duke University Department of Neurosurgery. 2015
- Sontag Distinguished Scientist Award. Sontag Foundation. 2015
- Matson Award for Best Basic Science Research. New England Neurosurgical Society. 2013
- Preuss Award for Neuro-Oncologic Research. Congress of Neurological Surgeons. 2013
- NIH Loan Repayment Program Award. National Institutes of Health. 2011
- Resident Teaching Award. Tufts University School of Medicine. 2008
- Neurosurgery Award. Duke University Department of Neurosurgery. 2007
- Keynote Speaker. Society for Neuro-Oncology. 2006
- Eugene A. Stead Scholar. Duke University School of Medicine. 2001
- Medical Scientist Training Program Fellowship. National Institutes of Health. 2001
- Cornell-Diamante Scholarship. Cornell University. 1999
- Merrill Presidential Scholar. Cornell University. 1999
- Nanaline H. Duke Scholar. Duke University School of Medicine. 1999
- MOLMED 301B: Research in MOLMED - Oncological Sciences
- NSS 301B: Research in NSS
- PATHOL 793: Research Independent Study
In the News
- A Duke Team Just Found Missing Immune Cells That Could Fight Lethal Brain Tumors (Aug 13, 2018 | Duke Health News)
- Duke neurosurgeon: Many factors in McCain's favor as he undergoes cancer treatment (Jul 20, 2017)
- Chongsathidkiet, P; Jackson, C; Koyama, S; Loebel, F; Cui, X; Farber, SH; Woroniecka, K; Elsamadicy, AA; Dechant, CA; Kemeny, HR; Sanchez-Perez, L; Cheema, TA; Souders, NC; Herndon, JE; Coumans, J-V; Everitt, JI; Nahed, BV; Sampson, JH; Gunn, MD; Martuza, RL; Dranoff, G; Curry, WT; Fecci, PE, Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors., Nature Medicine (2019) [10.1038/s41591-019-0355-0] [abs].
- Suryadevara, CM; Desai, R; Farber, SH; Choi, BD; Swartz, AM; Shen, SH; Gedeon, PC; Snyder, DJ; Herndon, JE; Healy, P; Reap, EA; Archer, GE; Fecci, PE; Sampson, JH; Sanchez-Perez, L, Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol 25 no. 1 (2019), pp. 358-368 [10.1158/1078-0432.ccr-18-1211] [abs].
- Tanksley, J; Adamson, J; Torok, J; Kim, GJ; Floyd, SR; Fecci, P; Kirkpatrick, JP, Surgical Cavities Exhibit Substantial Remodeling Post Resection of Brain Metastases: Implications for Stereotactic Radiosurgery (SRS), International Journal of Radiation Oncology, Biology, Physics, vol 102 no. 3 (2018), pp. S151-S151 [10.1016/j.ijrobp.2018.06.365] [abs].
- Woroniecka, K; Fecci, PE, T-cell exhaustion in glioblastoma, Oncotarget, vol 9 no. 82 (2018), pp. 35287-35288 [abs].
- Atik, AF; Suryadevara, CM; Schweller, RM; West, JL; Healy, P; Herndon, JE; Congdon, KL; Sanchez-Perez, L; McLendon, RE; Archer, GE; Fecci, P; Sampson, JH, Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells, Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, vol 56 (2018), pp. 163-168 [10.1016/j.jocno.2018.06.005] [abs].